JP2025508075A5 - - Google Patents

Info

Publication number
JP2025508075A5
JP2025508075A5 JP2024553452A JP2024553452A JP2025508075A5 JP 2025508075 A5 JP2025508075 A5 JP 2025508075A5 JP 2024553452 A JP2024553452 A JP 2024553452A JP 2024553452 A JP2024553452 A JP 2024553452A JP 2025508075 A5 JP2025508075 A5 JP 2025508075A5
Authority
JP
Japan
Application number
JP2024553452A
Other languages
Japanese (ja)
Other versions
JPWO2023172890A5 (https=
JP2025508075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063821 external-priority patent/WO2023172890A2/en
Publication of JP2025508075A publication Critical patent/JP2025508075A/ja
Publication of JPWO2023172890A5 publication Critical patent/JPWO2023172890A5/ja
Publication of JP2025508075A5 publication Critical patent/JP2025508075A5/ja
Pending legal-status Critical Current

Links

JP2024553452A 2022-03-07 2023-03-07 抗ｉｌｔ２抗体及びその使用 Pending JP2025508075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268945P 2022-03-07 2022-03-07
US63/268,945 2022-03-07
PCT/US2023/063821 WO2023172890A2 (en) 2022-03-07 2023-03-07 Anti-ilt2 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2025508075A JP2025508075A (ja) 2025-03-21
JPWO2023172890A5 JPWO2023172890A5 (https=) 2026-03-12
JP2025508075A5 true JP2025508075A5 (https=) 2026-03-12

Family

ID=87935886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553452A Pending JP2025508075A (ja) 2022-03-07 2023-03-07 抗ｉｌｔ２抗体及びその使用

Country Status (10)

Country Link
US (1) US20250109201A1 (https=)
EP (1) EP4490196A2 (https=)
JP (1) JP2025508075A (https=)
KR (1) KR20250004950A (https=)
CN (1) CN119365487A (https=)
AU (1) AU2023231622A1 (https=)
CA (1) CA3254318A1 (https=)
IL (1) IL315487A (https=)
MX (1) MX2024010982A (https=)
WO (1) WO2023172890A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025059304A2 (en) * 2023-09-12 2025-03-20 Agenus Inc. Methods of treating cancer using ilt2 antibodies and combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2541360A1 (en) * 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EP3580239A4 (en) * 2017-02-09 2021-07-28 Bluefin Biomedicine, Inc. ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES
MX2021015024A (es) * 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
AU2021265801B2 (en) * 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2025508075A5 (https=)
CL2025003787A1 (es) Un aparato para operar una pistola de licor de una caldera de recuperación, una caldera de recuperación y un método de operación del aparato.
BR102023014872A2 (https=)
BR102023009641A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307048557S (https=)
BY13143U (https=)
BY13159U (https=)
BY13158U (https=)
BY13157U (https=)
BY13156U (https=)
BY13155U (https=)
BY13153U (https=)
BY13152U (https=)
BY13151U (https=)
BY13150U (https=)
BY13161U (https=)
CN307049340S (https=)
CN307049252S (https=)
CN307049003S (https=)
CN307048834S (https=)
BY13176U (https=)